Cargando…
A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care
INTRODUCTION: Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke 4 to 5-fold. The first choice of anticoagulant therapy (AT) is the vitamin K antagonist (VKA). Contraindication to VKA or poor control of the International Normalized Ratio leads to...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779750/ https://www.ncbi.nlm.nih.gov/pubmed/29504981 http://dx.doi.org/10.1097/MD.0000000000009578 |
_version_ | 1783294602871046144 |
---|---|
author | Dalmau Llorca, Maria Rosa Gonçalves, Alessandra Queiroga Forcadell Drago, Emma Fernández-Sáez, José Hernández Rojas, Zojaina Pepió Vilaubí, Josep Maria Rodríguez Cumplido, Dolores Morral Parente, Rosa Maria Aguilar Martín, Carina |
author_facet | Dalmau Llorca, Maria Rosa Gonçalves, Alessandra Queiroga Forcadell Drago, Emma Fernández-Sáez, José Hernández Rojas, Zojaina Pepió Vilaubí, Josep Maria Rodríguez Cumplido, Dolores Morral Parente, Rosa Maria Aguilar Martín, Carina |
author_sort | Dalmau Llorca, Maria Rosa |
collection | PubMed |
description | INTRODUCTION: Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke 4 to 5-fold. The first choice of anticoagulant therapy (AT) is the vitamin K antagonist (VKA). Contraindication to VKA or poor control of the International Normalized Ratio leads to the administration of direct-acting oral anticoagulants. There is a trend toward inadequate AT in nonvalvular AF (NVAF) patients. Aim: To evaluate the impact of the implementation of a decision support tool linked to the digital clinical history on the adequacy of AT, the incidence of complications, and the mortality in patients with NVAF in primary care centers (PCCs) of the Catalan Institute of Health (ICS). METHODS AND ANALYSIS: Randomized clinical trial in 287 PCCs, formed by 2 groups (intervention and control). Population: patients controlled in PCCs, diagnosed with NVAF 1 year before the implementation of the decision support tool and with VKA treatment over a minimum of 1 year. A simple randomization method will be performed at a sector level. The decision support tool will be available for 1 year. The time in therapeutic range (TTR) will be available in the digital clinical history only to professionals of the intervention group. The information system for primary care research development database will be used for the data extraction. Statistical analysis will be done at 3 time points: before the implementation of the tool, at 1 year, and at 2 years after the beginning of the intervention. Multilevel (patient and professional levels) logistic regression models will be used to estimate the effect of the intervention. ETHICS AND DISSEMINATION: This study protocol was approved by the Ethical Committee of Clinical Investigation of the Institut Universitari d’Investigació en Atenció Primària Jordi Gol (code P17/091). Articles will be published in scientific journals. TRIAL REGISTRATION: Clinical-Trials.gov: NCT03367325. |
format | Online Article Text |
id | pubmed-5779750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-57797502018-02-05 A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care Dalmau Llorca, Maria Rosa Gonçalves, Alessandra Queiroga Forcadell Drago, Emma Fernández-Sáez, José Hernández Rojas, Zojaina Pepió Vilaubí, Josep Maria Rodríguez Cumplido, Dolores Morral Parente, Rosa Maria Aguilar Martín, Carina Medicine (Baltimore) 6400 INTRODUCTION: Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke 4 to 5-fold. The first choice of anticoagulant therapy (AT) is the vitamin K antagonist (VKA). Contraindication to VKA or poor control of the International Normalized Ratio leads to the administration of direct-acting oral anticoagulants. There is a trend toward inadequate AT in nonvalvular AF (NVAF) patients. Aim: To evaluate the impact of the implementation of a decision support tool linked to the digital clinical history on the adequacy of AT, the incidence of complications, and the mortality in patients with NVAF in primary care centers (PCCs) of the Catalan Institute of Health (ICS). METHODS AND ANALYSIS: Randomized clinical trial in 287 PCCs, formed by 2 groups (intervention and control). Population: patients controlled in PCCs, diagnosed with NVAF 1 year before the implementation of the decision support tool and with VKA treatment over a minimum of 1 year. A simple randomization method will be performed at a sector level. The decision support tool will be available for 1 year. The time in therapeutic range (TTR) will be available in the digital clinical history only to professionals of the intervention group. The information system for primary care research development database will be used for the data extraction. Statistical analysis will be done at 3 time points: before the implementation of the tool, at 1 year, and at 2 years after the beginning of the intervention. Multilevel (patient and professional levels) logistic regression models will be used to estimate the effect of the intervention. ETHICS AND DISSEMINATION: This study protocol was approved by the Ethical Committee of Clinical Investigation of the Institut Universitari d’Investigació en Atenció Primària Jordi Gol (code P17/091). Articles will be published in scientific journals. TRIAL REGISTRATION: Clinical-Trials.gov: NCT03367325. Wolters Kluwer Health 2018-01-19 /pmc/articles/PMC5779750/ /pubmed/29504981 http://dx.doi.org/10.1097/MD.0000000000009578 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 6400 Dalmau Llorca, Maria Rosa Gonçalves, Alessandra Queiroga Forcadell Drago, Emma Fernández-Sáez, José Hernández Rojas, Zojaina Pepió Vilaubí, Josep Maria Rodríguez Cumplido, Dolores Morral Parente, Rosa Maria Aguilar Martín, Carina A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care |
title | A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care |
title_full | A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care |
title_fullStr | A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care |
title_full_unstemmed | A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care |
title_short | A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care |
title_sort | new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: a randomized clinical trial in primary care |
topic | 6400 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779750/ https://www.ncbi.nlm.nih.gov/pubmed/29504981 http://dx.doi.org/10.1097/MD.0000000000009578 |
work_keys_str_mv | AT dalmaullorcamariarosa anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT goncalvesalessandraqueiroga anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT forcadelldragoemma anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT fernandezsaezjose anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT hernandezrojaszojaina anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT pepiovilaubijosepmaria anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT rodriguezcumplidodolores anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT morralparenterosamaria anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT aguilarmartincarina anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT dalmaullorcamariarosa newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT goncalvesalessandraqueiroga newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT forcadelldragoemma newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT fernandezsaezjose newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT hernandezrojaszojaina newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT pepiovilaubijosepmaria newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT rodriguezcumplidodolores newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT morralparenterosamaria newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare AT aguilarmartincarina newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare |